- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05547568
A Nomogram to Predict Major Postoperative Complications After Cytoreductive Surgery and HIPEC Based on Pre and Peroperative Criteria: Which Patient Require Intensive Monitoring?
A Nomogram to Predict Major Postoperative Complications After Cytoreductive Surgery and HIPEC Based on Pre and Peroperative Criteria: Which Patient Require Intensive Monitoring? A Cohort Retrospective Study.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a retrospective study from a single center of a prospectively maintained database of patients who underwent cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis of various primitives. The postoperative monitoring was carried out by a daily clinical examination and laboratory tests were drawn every two days during the first postoperative week. All patients had a CT-scan when a postoperative complication was suspected or at postoperative day 7 before hospital discharge. All patients were followed up to 90 postoperative days. Collected variables included age, gender and body mass index (BMI), smoking, diabetes mellitus, American Society of Anesthesiology classification of physical health (ASA), nutritional status (albuminemia ≤ 35mg/L), preoperative hemoglobin level, tumor origin, synchronous/metachronous peritoneal carcinomatosis, preoperative chemotherapy and/or biotherapy, presence of ascites at surgery, Peritoneal Cancer Index, type and number of resected organs, type and number of anastomoses, and number of packed red blood cells transfused. Wedge resection, cauterization, or superficial excisions of the bowel wall were not recorded. Minor hepatectomy concerned wedge resections or resection of less than 3 hepatic. Postoperative complications, recorded up to postoperative day 90, were graded according to Clavien-Dindo classification.
The endpoint of this study was the occurrence of a major postoperative complication that was defined as a Clavien-Dindo ≥ 3 grade complication.
To build the multivariate model the investigators used a backward stepwise approach with removal of individual variables one by one starting with the highest p-value until all variables had a p-value lower than 0.05. Results were presented as Odds Ratio and 95% confidence interval. Based on the multivariate model with identified risk factors, a nomogram was constructed to predict major postoperative complication probability after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. The coefficients derived from the multivariate analysis were used as weights. The nomogram assessed the probability of major postoperative complication after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy by adding up the scores identified on the "Points" scale for each factor. The total score projected from the "Total points" axis to the "Risk of major postoperative complication" axis, indicated the probability of major postoperative complication occurrence after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. The calibration curve of the prediction model was plotted to compare the predicted and actual probability of major postoperative complication.
The concordance index (C-index) was reported as a measure of internal validation using both 10-fold cross-validations repeated for 20 times, and bootstrap validation of 200 resamples. The area under the receiver operating characteristic (ROC) curve (AUC) was used to evaluate the performance of the model. The AUC is an effective method for quantifying the discriminatory capacity of a nomogram to correctly predict patients at low or high risk of major postoperative complication.
The Youden Index, which maximizes the sum of sensitivity and specificity, was determined according to the ROC curve. At this threshold, the sensitivity, the specificity, the predictive positive value (PPV), the negative predictive value (NPV) and the overall diagnostic accuracy (i.e., probability for a patient to be classified correctly by the nomogram) were calculated. A calibration curve was used to show consistency between the observation frequency and prediction probability.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Reims, France, 51092
- CHU Reims
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients with peritoneal carcinomatosis from various origins.
- Suitable for curative surgery
- With a ECOG performance status ≤ 2
Exclusion Criteria:
- Age < 18 years old
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Retrospective
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Major postoperative complications (Dindo-Clavien ≥ 3 grade)
Time Frame: Follow-up to 90 postoperative days
|
Follow-up to 90 postoperative days
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2022Ao002*
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Peritoneal Carcinomatosis
-
Association Francaise de ChirurgieCompletedCarcinomatosis, PeritonealFrance
-
Hasselt UniversityZiekenhuis Oost-LimburgUnknownColorectal Peritoneal CarcinomatosisBelgium
-
Hospices Civils de LyonUnknownColorectal Peritoneal CarcinomatosisFrance
-
University of California, IrvineRecruitingPeritoneal Carcinomatosis | Gastrointestinal Peritoneal CarcinomatosisUnited States
-
Gustave Roussy, Cancer Campus, Grand ParisTerminatedPatients With Gastric Peritoneal CarcinomatosisFrance
-
Hospices Civils de LyonCompletedDigestive Peritoneal CarcinomatosisFrance
-
Uppsala UniversityCompletedColorectal Peritoneal CarcinomatosisSweden
-
AIO-Studien-gGmbHNeovii BiotechCompletedGastric Adenocarcinoma With Peritoneal Carcinomatosis | Siewert Type II Adenocarcinoma of Esophagogastric Junction With Peritoneal Carcinomatosis | Siewert Type III Adenocarcinoma of Esophagogastric Junction With Peritoneal CarcinomatosisGermany
-
M.D. Anderson Cancer CenterCompletedPeritoneal CancerUnited States
-
Carlos ChanInstitute of Quantitative Systems Pharmacology (IQSP)RecruitingPeritoneal CarcinomatosisUnited States
Clinical Trials on Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy
-
Hospices Civils de LyonCompletedOvarian Cancer | Peritoneal CarcinomaFrance
-
Hospices Civils de LyonCompletedGastric Cancer | Peritoneal CarcinomatosisFrance
-
The Netherlands Cancer InstituteUniversity Medical Center Groningen; UMC Utrecht; Erasmus Medical Center; Catharina...RecruitingPeritoneal Carcinomatosis | Stomach NeoplasmNetherlands
-
Affiliated Cancer Hospital & Institute of Guangzhou...Chongqing University Cancer Hospital; Xiangya Hospital of Central South University and other collaboratorsRecruitingFallopian Tube Cancer | Epithelial Ovarian Cancer | Primary Peritoneal CarcinomaChina
-
University Hospital TuebingenIcahn School of Medicine at Mount SinaiUnknownPeritoneal Cancer | Chemotherapy-Induced ChangeGermany
-
Kyungpook National University HospitalNot yet recruitingColorectal Cancer MetastaticKorea, Republic of
-
University Hospital, RouenRecruiting
-
Memorial Sloan Kettering Cancer CenterMayo Clinic; University of Chicago; University of Pittsburgh; Baptist Health South... and other collaboratorsActive, not recruitingOvarian Cancer | Peritoneal Cancer | Fallopian Tubes CancerUnited States
-
University of RegensburgHeinrich-Heine University, DuesseldorfTerminatedColorectal Cancer Metastatic | Peritoneal CarcinomatosisGermany
-
Zhejiang UniversityCompletedPeritoneal Carcinomatosis | Malignant Neoplasm of Large Intestine TNM Staging Primary Tumor (T) T4China